Drug Profile

K NK ID101

Alternative Names: K-NK cells; K-NK-ID101

Latest Information Update: 18 Mar 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kiadis Pharma
Developer Erasmus MC; Harbour BioMed Netherlands; Kiadis Pharma; Prothya BioSolutions; Utrecht University; Viroclinics-DDL
Class Monoclonal antibodies; Natural killer cell therapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

16 Apr 2021 Kiadis Pharma has been acquired by Sanofi
16 Feb 2021 Phase-I/II clinical trials in COVID-2019 infections in USA (Parenteral), prior to February 2021 (Kiadis Pharma pipeline, February 2021)
16 Sep 2020 Preclinical trials in COVID-2019 infections in Netherlands (Parenteral) prior to September 2020 (Kiadis Pharma pipeline, September 2020)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com